异环磷酰胺联合紫杉醇化疗治疗难治型小细胞肺癌临床观察

Clinical Observation of Ifosfamide with Taxol in the Treatment of Refractory Small Cell Lung Cancer

目的:观察异环磷酰胺(IFO)、紫杉醇(TAX)联合化疗治疗难治型小细胞肺癌的疗效及毒副反应。方法:32例难治型小细胞肺癌采用IFO 2.0静滴连用4d,美司钠(MESNA)400mg于IFO后0、4、8h静脉输注,TAX 150mg/m2第1天静脉输注。21d为1个周期。化疗2个周期评价疗效和毒副反应。结果:总有效率40.6%(13/32),疾病控制率68.8%(22/32),中位生存时间7.1个月。主要毒副反应为骨髓抑制。结论:以异环磷酰胺、紫杉醇联合化疗治疗小细胞肺癌能有效地提高患者近期疗效,毒副反应能够耐受。

Objective :To investigate the efficiency and toxicities of ifosfamide with taxol as the second line chemothera-py in the treatment of refractory small cell lung cancer (SCLC) .Methods :Thirty-two patients with refractory small cell lung cancer were received the chemotherapy :Ifosfamide 2 .0 d1~4 ,Mesna 400mg 0 ,4 ,8hours after ifosfamide ;taxol 150mg/m2 ,every 21 days was 1 cycle .The efficiency and toxicities were evaluated after 2 cycles of chemotherapy .Re-sults:The response rate was 40 .6% (13/32) ,disease control rate was 68 .8% (22/32) ,the median survival was 7 .1 months ,the main toxicity was myelosuppression .Conclusion:Ifosfamide combined with taxol as the second line chemo-therapy is effective in the treatment of refractory small cell lung cancer (SCLC) ,and the toxicities are mild .